Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
84 hedge funds and large institutions have $39.2M invested in Chinook Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 20 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
12% more capital invested
Capital invested by funds: $35.2M → $39.2M (+$4.08M)
5% less funds holding
Funds holding: 88 → 84 (-4)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.07M |
| 2 |
Goldman Sachs
New York
|
+$682K |
| 3 |
JP Morgan Chase
New York
|
+$335K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$304K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$295K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$2.65M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.31M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.07M |
| 4 |
BlackRock
New York
|
-$1.01M |
| 5 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$679K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
US Bancorp
Minneapolis,
Minnesota
| – | -$65 | -12 | -71% |
|
102
Simplex Trading
Chicago,
Illinois
| – | +$120 | +22 | New |
|
KDNY Hedge Fund Activity: Q4 2019 in Review
84 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2019, worth a combined $39.2M — up 12% from $35.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KDNY and 16 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 31 added.
The largest buyer was Renaissance Technologies, adding an estimated $2.07M. The largest seller was First Light Asset Management, exiting entirely with an estimated $2.65M sold.
- 84 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2019, down from 88 in Q3 2019.
- Funds reported $39.2M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2019, up 12% quarter-over-quarter.
- 16 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2019 and 20 closed out, a net change of -4 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $2.07M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2019 was First Light Asset Management, an estimated $2.65M sold.
Based on aggregated 13F filings for Q4 2019.